Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

Alexander M.M. Eggermont(Erasmus University Rotterdam), Stefan Suciu(European Organisation for Research and Treatment of Cancer), Rona M. MacKie(University of Glasgow), W. Ruka(The Maria Sklodowska-Curie National Research Institute of Oncology), Alessandro Testori(European Institute of Oncology), Wim H.J. Kruit(Erasmus University Rotterdam), Cornelis J.A. Punt(Radboud University Nijmegen), Michelle Delauney(Hôpital Pellegrin), François Salès(Institut Jules Bordet), Gerard Groenewegen(University Medical Center Utrecht), Dirk J. Ruiter(Radboud University Nijmegen), Izabella Jagiello(European Organisation for Research and Treatment of Cancer), Konstantin Stoitchkov(European Organisation for Research and Treatment of Cancer), Ulrich Keilholz(Freie Universität Berlin), Danielle Líénard(University Hospital of Lausanne)
The Lancet
October 1, 2005
Cited by 314

Abstract


Related Papers

No related papers found

Powered by citation graph analysis